# Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

> **NCT06757894** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 50 (estimated)

## Conditions studied

- Follicular Lymphoma (FL)

## Interventions

- **DRUG:** Zuberitamab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT06757894
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2034-02-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06757894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06757894, "Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06757894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*